![Lazar Mandinov](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Lazar Mandinov
Corporate Officer/Principal bij The European Society of Cardiology
Actieve functies van Lazar Mandinov
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
The European Society of Cardiology | Corporate Officer/Principal | - | - |
Loopbaan van Lazar Mandinov
Eerdere bekende functies van Lazar Mandinov
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BOSTON SCIENTIFIC CORPORATION | Hoofd Techniek/Wetenschap/O&O | - | - |
Maine Medical Center Research | Corporate Officer/Principal | - | - |
Mitralign, Inc.
![]() Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Hoofd Techniek/Wetenschap/O&O | - | - |
Opleiding van Lazar Mandinov
Medical University Sofia | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 4 |
Frankrijk | 2 |
Bulgarije | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Sectoraal
Health Technology | 3 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
BOSTON SCIENTIFIC CORPORATION | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Mitralign, Inc.
![]() Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Health Technology |
The European Society of Cardiology | |
Maine Medical Center Research |
- Beurs
- Insiders
- Lazar Mandinov
- Ervaring